Navigation Links
Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
Date:6/28/2010

ORLANDO, Fla., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.  The analysis showed that higher C-peptide levels had a statistically significant correlation with a decrease in two distinct measurements of glucose variability, confirming that C-peptide is a robust clinical marker for beta cell function which becomes impaired in type 1 diabetes.  Measurement of C-peptide has been endorsed by FDA as the primary endpoint for clinical trials of therapies that are designed to preserve beta cell function in new-onset type 1 diabetes and is the primary endpoint to evaluate the efficacy of otelixizumab in the DEFEND-1 clinical trial, with results from DEFEND-1 expected in the first half of 2011.  

The pre-dose baseline data from DEFEND-1 represents one of the first comprehensive studies to correlate higher C-peptide levels with lower blood glucose variability in patients with type 1 diabetes.  These results are clinically meaningful because blood glucose variability may be a risk factor for short- and long-term complications, including severe hypoglycemia and microvascular disease, in patients with type 1 diabetes.  The analysis from the DEFEND-1 study was presented at a poster session of the 70th Scientific Sessions of the American Diabetes Association (ADA) taking place June 25 through June 29 in Orlando, Florida. 

"We are gratified that the analysis of baseline data from our DEFEND-1 clinical trial may contribute to a better understanding of new-onset type 1 diabetes and
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
2. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
3. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
4. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
5. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
6. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
9. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
10. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
11. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Leading ... to capture critical product and market insights in ... benefits to employee-based studies, it is essential for ... own internal employees to capture critical business-related insights. ... benchmarking firm, Best Practices, LLC, most benchmarked companies ...
(Date:7/2/2015)... DIEGO , July 2, 2015 ResMed Inc. ... its fourth quarter and fiscal year ended June 30, 2015 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
(Date:7/2/2015)... LAUDERDALE, Fla. , July 2, 2015 /PRNewswire/ ... Co., is pleased to announce that its Consumer ... ("Insight Beverages") to Kerry Group plc (ISE: KRZ) ... on taste and nutrition systems, as well as ... beverage and pharmaceutical markets. Farlie Turner served as ...
Breaking Medicine Technology:Leveraging Employee Insights to Produce Cutting-Edge Market Research 2ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2
... Dec. 27, 2010 Boston Scientific Corporation (NYSE: ... J.P. Morgan Healthcare Conference in San Francisco. Ray ... presentation on Tuesday, January 11, 2011, beginning at approximately 9:30 ... and Chief Financial Officer, will join Mr. Elliott in a ...
... King Pharmaceuticals®, Inc. (NYSE: KG ... today announced that King has resubmitted a New Drug Application ... Administration (FDA) in response to a Complete Response letter received ... 2 resubmission with a six month review cycle. ...
Cached Medicine Technology:King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY® 2King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY® 3
(Date:7/3/2015)... ... ... Hope Food Bank will hopefully be getting a large donation of canned food items ... Greenville SC are making it their mission to collect as many canned items as possible. ... from the public as well. As part of the canned food drive, these local chiropractors ...
(Date:7/3/2015)... ... ... Scientists at several top US cancer centers believe they now know why certain people ... read the complete story , just posted on the Surviving Mesothelioma website. , ... York University exposed mice with a mutation on the tumor suppressor gene called BAP1 ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... took place on June 25, 2015 at 1:00pm. The Association welcomed speaker C. ... pertaining to injured bicyclists and practical points of investigating these types of cases. ...
(Date:7/3/2015)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... Director of its Frisco facility. , “We are pleased to announce that Dr. Manzanares ... Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Manzanares received ...
(Date:7/3/2015)... ... ... Celebrity Dresses is currently running a promotion through July 30th. Anyone who orders party ... get 10% discount on orders that are over $100. , The promotion is automatically ... or remember redemption codes. , There is a low price guarantee at The ...
Breaking Medicine News(10 mins):Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2
... endpoints , , VALENCIA, Calif., Dec. 4 ... announced that it has met the primary endpoints of its final two ... insulin product. The company expects to disclose more details of the top-line ... diabetes (studies 030 and 102) by mid-December. , ...
... bring sports flavor to the conversation about a serious men,s ... CARY, N.C., Dec. 4 College basketball analyst and sports ... Interruption Michael Wilbon have teamed up with ESPN, The V ... an effort to create a national discussion about the often ...
... Dec. 4 Nu Skin Enterprises, Inc.,(NYSE: NUS ... its,annual Investor Day presentation this morning at 9 a.m. at ... presentation, senior,management will discuss the company,s operational results and outline ... Nu Skin business is on track and we look forward ...
... 4 The Ensign Group, Inc.,(Nasdaq: ENSG ... skilled nursing,rehabilitative care services and assisted living companies, announced ... Alta, an 85-bed skilled,nursing facility in Salt Lake City, ... Center. , (Logo: ...
... less than half of patients with necrotizing soft tissue ... infections, researchers have found two simple blood tests can ... bacteria," according to a study in the December issue ... Researchers at the Los Angeles Biomedical Research Institute at ...
... ProVet , a multi-function patient monitor, provides veterinarians with superior monitoring ... ... (Vocus) December 4, 2008 -- DRE Veterinary — a premier ... Waveline ProVet , a lightweight vital signs monitor that displays as ...
Cached Medicine News:Health News:MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 2Health News:MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 3Health News:ESPN's Dick Vitale and Michael Wilbon Stand Up in the Fight Against Prostate Cancer 2Health News:ESPN's Dick Vitale and Michael Wilbon Stand Up in the Fight Against Prostate Cancer 3Health News:ESPN's Dick Vitale and Michael Wilbon Stand Up in the Fight Against Prostate Cancer 4Health News:Nu Skin Enterprises Offers 2009 Guidance During Annual Investor Day 2Health News:Nu Skin Enterprises Offers 2009 Guidance During Annual Investor Day 3Health News:The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility 2Health News:Blood tests can help detect presence of necrotizing soft tissue infections 2Health News:DRE Veterinary Introduces Dynamic Flat Panel Monitor 2Health News:DRE Veterinary Introduces Dynamic Flat Panel Monitor 3Health News:DRE Veterinary Introduces Dynamic Flat Panel Monitor 4
... Response catheters comprise the world's broadest ... electrophysiology procedures. Their advanced catheter design ... torque response with a soft, atraumatic ... French sizes, Supreme and Response catheters ...
... St. Jude Medical's line of guiding ... CSTA, RAMP, and 2 piece steerable, ... electrophysiology catheters when the varying curves ... aid physician technique. St. Jude Medical ...
Lumenis 1000 Integrated Slit Lamp Fully-integrated biomicroscope slit lamp laser delivery system, complete with built-in LaserLink, parallel optics, magnification changer, micromanipulator and multi...
Novus 30001 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
Medicine Products: